Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

This study investigated Farxiga in heart failure patients with reduced ejection fraction (HFrEF). ... to explore Farxiga as a potential new treatment option for heart failure patients,” he added.

Latest news

AZ claims first-in-class win for Farxiga in heart failure

Meanwhile, Farxiga is also being studied in HFpEF in the DELIVER trial as well as the DETERMINE study, which is enrolling both HFrEF and HFpEF patients. ... a heart failure claim for Farxiga in diabetic and non-diabetic HFrEF, and shares rose almost 2%
AZ says Farxiga cuts kidney disease in type 2 diabetes

Helps in SGLT2 inhibitor battle with Jardiance. AstraZeneca has more data showing that its SGLT2 inhibitor Farxiga can prevent complications of type 2 diabetes, this time showing it can reduce the ... Farxiga is already growing nicely for AZ, with sales
J&J’s Invokana first SGLT2 to show kidney disease benefits

The trial puts Invokana one step ahead of rivals, such as AstraZeneca, the renal outcomes study for its SGLT2 drug Farxiga due in November 2020.
Success for AZ, setback for Sanofi in type 1 diabetes

The EMA acknowledges the risk but has nevertheless approved Farxiga, while it seems that the FDA has taken a more cautious stance on the side effect and decided not to approve
Cancer drugs and China sustain AZ’s return to growth

Among AZ’s older products, diabetes therapy Farxiga (dapagliflozin) grew 30% to consolidate its blockbuster status with sales of $1.39bn, with an even faster take-up in emerging markets, while

More from news
Approximately 7 fully matching, plus 26 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Client Services Director- Flexible Working: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Events Executive: DOE

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Subscribe to our email news alerts

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...